Publications in collaboration with researchers from University of Padua (12)

2023

  1. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  2. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

2020

  1. 2018 updated European League against Rheumatism evidence-based recommendations for the diagnosis of gout

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 1, pp. 31-38

2017

  1. 2016 updated EULAR evidence-based recommendations for the management of gout

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 29-42

2014

  1. Improving cardiovascular and renal outcomes in gout: What should we target?

    Nature Reviews Rheumatology, Vol. 10, Núm. 11, pp. 654-661

2012

  1. Gout: Why is this curable disease so seldom cured?

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 11, pp. 1765-1770

2011

  1. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 571-575

  2. European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 563-570

2010

  1. International position paper on febuxostat

    Clinical Rheumatology, Vol. 29, Núm. 8, pp. 835-840

2006

  1. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)

    Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1301-1311

  2. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

    Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1312-1324